We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
Read MoreHide Full Article
Key Takeaways
OPK gained 12.4% in four weeks as operating loss narrowed and gross margin improved to 48.9%.
BioReference posted $4.8M in operating income, helped by lower service costs and an earnout gain.
OPKO Health faces a net loss, rising R&D costs and clinical milestones expected in late 2026.
OPKO Health, Inc. (OPK - Free Report) shares have gained 12.4% in the past four weeks, putting recent operating improvement and upcoming clinical milestones in focus.
The rally has support from narrower losses, better margins and favorable estimate revisions. Still, OPKO remains loss-making, and much of its longer-term upside depends on early-stage clinical execution and further progress at BioReference.
OPK's Past-Month Gain Meets Better Operating Leverage
Second-quarter operating loss narrowed to $7 million from $60 million a year earlier. Gross profit rose to $80 million from $49.4 million, while gross margin expanded to 48.9% from 31.5%.
BioReference also moved into the black, posting operating income of $4.8 million versus an $18.2 million loss a year earlier. The improvement followed lower service costs and an $18.1 million earnout gain tied to the oncology asset sale. Labcorp Holdings Inc. (LH - Free Report) completed its acquisition of those select BioReference oncology and related clinical-testing assets in September 2025.
Pharmaceutical revenues increased 59.8% year over year to $89 million. Product revenues rose 5.4% to $42.9 million, helped by higher volumes in Spain and Mexico and favorable foreign exchange, while Rayaldee revenues increased to $8.1 million from $7.2 million.
Intellectual-property and other revenues also increased sharply, including $29.4 million recognized from shares received under the amended Nicoya agreement. Pfizer Inc. (PFE - Free Report) , which commercializes NGENLA, contributed a $6.4 million quarterly profit share, up from $6.1 million a year earlier.
Image Source: Zacks Investment Research
OPK's Pipeline Adds Multiple Late-2026 Catalysts
ModeX's MDX2001 Phase I program is expected to finish dose escalation and regimen optimization by the third or early fourth quarter of 2026. Early data are targeted for presentation in late 2026 or early 2027. BARDA-funded MDX2301 is also expected to produce early results in that window after Phase I enrollment wraps up.
The Merck-funded MDX2201 Epstein-Barr virus vaccine has completed Phase I, with analysis expected to inform Phase II design by year-end 2026. MDX3001, OPKO's in vivo CAR-T candidate, is in IND-enabling studies and is targeted to enter first-in-human testing in late 2026 or early 2027.
OPKO Health Still Faces Profitability and Execution Risk
The operating improvement has not eliminated the central risk. OPKO reported a second-quarter net loss of $8.4 million, while research and development expense increased 9.3% year over year to $33.2 million as several programs moved through early clinical work.
BioReference's restructuring also remains unfinished. Management is reducing costs and shifting selected low-value esoteric tests to partners, but broader 4Kscore adoption in primary care depends on Medicare policy changes. That reimbursement uncertainty could delay one of the retained diagnostics business's larger growth opportunities.
Image Source: Zacks Investment Research
OPK's Momentum Leads Its Mixed Style Profile
OPK's recent price action is its clearest near-term positive, but the broader setup is mixed. The stock currently carries a Zacks Rank #3 (Hold). The Zacks Consensus Estimate for the current fiscal year's loss has improved over the past four weeks, while the stock's 12.4% four-week gain supports its Momentum Score of A. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The other Style Scores are less favorable. OPK has a Growth Score of C, Value Score of F and VGM Score of C. Because Style Scores are designed to complement the Zacks Rank, the combination points to favorable momentum without the stronger across-the-board profile typically associated with top-ranked stocks carrying A or B scores. Continued operating gains and successful clinical execution could help sustain interest, but the present ratings support a measured view of the rally.
View the Zacks #1 Rank List
Image: Bigstock
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
Key Takeaways
OPKO Health, Inc. (OPK - Free Report) shares have gained 12.4% in the past four weeks, putting recent operating improvement and upcoming clinical milestones in focus.
The rally has support from narrower losses, better margins and favorable estimate revisions. Still, OPKO remains loss-making, and much of its longer-term upside depends on early-stage clinical execution and further progress at BioReference.
OPK's Past-Month Gain Meets Better Operating Leverage
Second-quarter operating loss narrowed to $7 million from $60 million a year earlier. Gross profit rose to $80 million from $49.4 million, while gross margin expanded to 48.9% from 31.5%.
BioReference also moved into the black, posting operating income of $4.8 million versus an $18.2 million loss a year earlier. The improvement followed lower service costs and an $18.1 million earnout gain tied to the oncology asset sale. Labcorp Holdings Inc. (LH - Free Report) completed its acquisition of those select BioReference oncology and related clinical-testing assets in September 2025.
OPKO Health, Inc. Price and EPS Surprise
OPKO Health, Inc. price-eps-surprise | OPKO Health, Inc. Quote
OPKO Health Gets More Help From Pharmaceuticals
Pharmaceutical revenues increased 59.8% year over year to $89 million. Product revenues rose 5.4% to $42.9 million, helped by higher volumes in Spain and Mexico and favorable foreign exchange, while Rayaldee revenues increased to $8.1 million from $7.2 million.
Intellectual-property and other revenues also increased sharply, including $29.4 million recognized from shares received under the amended Nicoya agreement. Pfizer Inc. (PFE - Free Report) , which commercializes NGENLA, contributed a $6.4 million quarterly profit share, up from $6.1 million a year earlier.
Image Source: Zacks Investment Research
OPK's Pipeline Adds Multiple Late-2026 Catalysts
ModeX's MDX2001 Phase I program is expected to finish dose escalation and regimen optimization by the third or early fourth quarter of 2026. Early data are targeted for presentation in late 2026 or early 2027. BARDA-funded MDX2301 is also expected to produce early results in that window after Phase I enrollment wraps up.
The Merck-funded MDX2201 Epstein-Barr virus vaccine has completed Phase I, with analysis expected to inform Phase II design by year-end 2026. MDX3001, OPKO's in vivo CAR-T candidate, is in IND-enabling studies and is targeted to enter first-in-human testing in late 2026 or early 2027.
OPKO Health Still Faces Profitability and Execution Risk
The operating improvement has not eliminated the central risk. OPKO reported a second-quarter net loss of $8.4 million, while research and development expense increased 9.3% year over year to $33.2 million as several programs moved through early clinical work.
BioReference's restructuring also remains unfinished. Management is reducing costs and shifting selected low-value esoteric tests to partners, but broader 4Kscore adoption in primary care depends on Medicare policy changes. That reimbursement uncertainty could delay one of the retained diagnostics business's larger growth opportunities.
Image Source: Zacks Investment Research
OPK's Momentum Leads Its Mixed Style Profile
OPK's recent price action is its clearest near-term positive, but the broader setup is mixed. The stock currently carries a Zacks Rank #3 (Hold). The Zacks Consensus Estimate for the current fiscal year's loss has improved over the past four weeks, while the stock's 12.4% four-week gain supports its Momentum Score of A. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The other Style Scores are less favorable. OPK has a Growth Score of C, Value Score of F and VGM Score of C. Because Style Scores are designed to complement the Zacks Rank, the combination points to favorable momentum without the stronger across-the-board profile typically associated with top-ranked stocks carrying A or B scores. Continued operating gains and successful clinical execution could help sustain interest, but the present ratings support a measured view of the rally.